| 查看: 952 | 回复: 2 | ||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | ||
小木虫刘树青木虫 (著名写手)
夜未眠
|
[求助]
求大神翻译 只有一段哦,谢谢
|
|
|
In the future, it is likely that ctDNA and CTCs will have complementary roles as cancer biomarkers although separate approaches may have distinct advantages in specificclinicalcontexts. ctDNA analysis is appealing due to the ease with which plasma can be collected and analyzed without the prior need to enrich and isolate a rare population of cells. For this reason, ctDNA analysis is likely to be the preferred option for genotyping and monitoring treatment response. The analysis of ctDNA can be applied as a high-throughput strategy for the assessment of clinical samples, but is limited to the analysis of point mutations, structural rearrangements, copy number aberrations and changes in DNA methylation. In contrast, the analysis of CTCs provides the unique opportunity to study the whole cell, allowing DNA, RNA and protein-based molecular profiling, and the opportunity for functional studies to guide personalized treatment selection. Although the analysis of both ctDNA and CTCs pose several technical challenges, ongoing improvements are expected over coming years, and both approaches hold great promise as biomarkers in various facets of cancer management. Technological advances might allow in the future, the use of a liquid biopsy (CTCs or ctDNA) for earlier cancer diagnosis or detection of disease relapse/progression. However, it is not known if earlier detection will lead to improved patient outcomes. This will become possible only if effective treatments are available to target early recurrences. Another open question is whether the liquid biopsy will complement analysis of primary tumor or metastases for tailoring treatment selection. Ongoing interventional clinical trials using CTC detection and characterization by CellSearch® will provide initial answers on the above question. Future research will be focused on optimizing and standardizing new technologies for both ctDNA and CTC analysis, demonstrating appropriate analytical and clinical validity as well as establishing the clinical utility of ctDNA and CTC testing through appropriately designed prospective clinical trials. |
回复此楼» 猜你喜欢
售SCI一区T0P文章，我:8.O55.1.O.54,科目全,可十急
已经有5人回复
-
售SCI一区T0P文章，我:8.O.55.1.O.54,科目齐全,可+急
已经有5人回复
-
filecode，4个jtjc了
已经有11人回复
-
欢迎发来filecode的Mz6后的代码验证其规律
已经有117人回复
-
filecode=后面第一个是大写字母
已经有12人回复
-
为什么余额宝的年化利率越来越低？主要原因有哪些？
已经有4人回复
-
今天放榜吗？
已经有13人回复
-
今天基金会出结果吗？20260819
已经有8人回复
-
2027广东省杰青
已经有10人回复
-
朋友圈看到的
已经有8人回复
3楼2016-03-29 07:58:13
追梦青年LWQ
金虫 (正式写手)
- 应助: 0 (幼儿园)
- 金币: 1096.3
- 散金: 444
- 红花: 2
- 帖子: 355
- 在线: 45.7小时
- 虫号: 3688586
- 注册: 2015-02-14
- 专业: 机械工程
2楼2016-03-27 08:02:21
